As rivals look to carve up its blockbuster revenue, Novartis’ Cosentyx registers remarkably consistent effect for psoriasis
A decade after the very first psoriasis patient was treated with Cosentyx (secukinumab), Novartis is rolling out a fresh set of data underscoring just how durable the response rates are among patients taking the therapy.
In a 5-year followup, researchers for Novartis $NVS say that skin clearance rates have remained virtually unchanged for this IL-17A blockbuster. Looking at PASI 75/90/100, the one-year scores were 89%, 69% and 44%. At year five the PASI rates lined up at 89%, 66% and 41%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.